Xanamem™ is being developed as a potential drug for Alzheimer's disease. This study drug has
been designed to change the cortisol levels in the brain. Cortisol is a naturally occurring
hormone in the body. It is believed that reducing the level of cortisol will be a benefit in
the treatment of Alzheimer's disease.
The XanaHES study is testing the safety and tolerability of Xanamem. It is planned to enrol
approximately 84 participants, male and female aged from 50 to 75 who are in good health, in
the study at 1 centre in Australia.
The XanaHES Phase I study is a single-blind study. Subjects will be randomised to receive
either 20mg once daily Xanamem or Placebo in cohort 1. Once all subjects have completed the
study treatment of 12 weeks, a dose escalation committee will decide if a new cohort, cohort
2, with 30mg once daily vs placebo is started.